Quick Answer
Roivant Sciences Ltd. reported Stockholders Equity of $4.69 billion for the year ending 2025.
- Roivant Sciences Ltd. showed a decrease of -21.5% in Stockholders Equity from 2024 to 2025.
- This data is from Roivant Sciences Ltd.'s annual report (Form 10-K), filed with the SEC on May 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $1.72 billion | Q3 2021: $2.04 billion | Q4 2021: $1.87 billion | Q2 2022: $1.38 billion | Q3 2022: $1.16 billion | Q4 2022: $955.52 million | Q2 2023: $910.73 million | Q3 2023: $948.53 million | Q4 2023: $6.09 billion | Q2 2024: $5.44 billion | Q3 2024: $5.15 billion | Q4 2024: $5.19 billion | Q1 2025: $4.69 billion | Q2 2025: $4.35 billion | Q3 2025: $4.36 billion | Q4 2025: $4.27 billion.
- Over the full 5 years of available data (2021 to 2025), Roivant Sciences Ltd.'s Stockholders Equity has grown by 160.7%.
- Historical annual values: Fiscal year 2025: $4.69 billion | Fiscal year 2024: $5.97 billion | Fiscal year 2023: $1.16 billion | Fiscal year 2022: $1.66 billion | Fiscal year 2021: $1.80 billion.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: